PIK3CD and breast cancer: Furthermore, combination of multi-node PI3K/AKT/mTOR inhibition with paclitaxel – even at paclitaxel doses with relatively modest monotherapy efficacy – produced profound tumour growth inhibition and tumour regression in preclinical models of endometrial and breast cancer.